Evidence is continuously updated
In order to offer the best possible treatment options, Microbiome Center continuously updates the evidence of all available ingredients.
A recent example is the addition of evidence for Bacillus clausii UBBC-07. New studies have been published about its effect on upper respiratory tract infections, prevention of radiation therapy induced mucositis, and ulcerative colitis (1-3). A well-conducted RCT with 90 children showed that, compared to placebo, treatment with B. clausii UBBC-07 led to a large reduction in the mean number, duration, and severity of upper respiratory tract infections (1). Another RCT investigated whether this strain can reduce side effects of radiation therapy of head and neck cancer patients, in particular mucositis (2). It was found that the time to onset of mucositis was longer, duration of mucositis was shorter, and, most prominently, that the severity of mucositis was substantially less. A third RCT in IBD patients showed a benefit of B. clausii UBBC-07 on disease activity score and markers of inflammation compared to placebo in ulcerative colitis patients but not in Crohn’s disease patients. This shows the importance of making a distinction between these two different diseases within the IBD cluster.
Another example of a strain with recently added evidence is Bacillus coagulans Unique IS-2. This strain was investigated for its effect on ulcerative colitis too, with similar findings as the aforementioned B. clausii UBBC-07 study (4). Interestingly, there was already evidence that B. coagulans Unique IS-2 is effective in constipation, and a new well-conducted RCT confirms that this strain has a large effect on constipation (5).
These and other evidence updates are continuously processed and added to the Advice Aid, so that the suggested personalized preparations are always based on the best available knowledge and the most complete overview of the scientific evidence. All studies can be found under the i-button of each ingredient.
References: